ProMetic Life Sciences Inc. (TSE:PLI) shares fell 20% during trading on Wednesday . The company traded as low as C$0.04 and last traded at C$0.04. 8,151,561 shares were traded during mid-day trading, an increase of 189% from the average session volume of 2,817,786 shares. The stock had previously closed at C$0.05.
A number of research analysts have issued reports on PLI shares. Canaccord Genuity cut ProMetic Life Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. National Bank Financial lowered their price objective on ProMetic Life Sciences from C$0.45 to C$0.30 in a research note on Thursday, April 4th. Echelon Wealth Partners cut ProMetic Life Sciences from a “speculative buy” rating to a “hold” rating in a research note on Tuesday, April 2nd. Finally, Royal Bank of Canada lowered their price objective on ProMetic Life Sciences from C$1.25 to C$0.70 and set an “outperform” rating for the company in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. ProMetic Life Sciences has an average rating of “Hold” and a consensus price target of C$0.43.
The company has a market cap of $1.04 billion and a PE ratio of -0.19. The company has a quick ratio of 0.65, a current ratio of 0.95 and a debt-to-equity ratio of 238.62.
COPYRIGHT VIOLATION NOTICE: “ProMetic Life Sciences (PLI) Trading Down 20%” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/22/prometic-life-sciences-pli-trading-down-20.html.
ProMetic Life Sciences Company Profile (TSE:PLI)
Prometic Life Sciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals.
Featured Article: Fibonacci Channel
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.